Pricing Log in Create free account
Saturday 10 October 2026 Export all PFE data to Excel Powerpack

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

28.28 0.46 +1.65%
Market cap
$158.6B
P/E
37.2×
Fwd P/E
12.2×
Dividend yield
6.08%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Pfizer Inc. (PFE) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Jun 28, 2026 P1I2: 37 added · 7 removed · 50 modified
P2I1A: no comparison — incorporated by reference
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 18, 2026 7.01 Regulation FD disclosure
8-K Jun 18, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
10-Q Mar 29, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 23, 2026 5.07 Submission of matters to a vote of security holders
10-K Dec 31, 2025 1: 35 added · 24 removed · 77 modified
1A: 8 added · 2 removed · 48 modified
7: 39 added · 50 removed · 71 modified
8-K Feb 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 16, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 18, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 13, 2025 8.01 Other events
10-Q Sep 28, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 29, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.